Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform, designed to transform anterior segment diagnostics and streamline practice workflow. “Building upon our previous CE-marking, we are thrilled that the ANTERION…
Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid. Novocure will present three new posters on Tumor Treating Fields (TTFields) therapy, including an analysis of…
GE HealthCare (Nasdaq: GEHC) today announced new data from a pilot study conducted with Cleveland Clinic evaluating the Portrait Mobile wireless and wearable monitoring solution. The results demonstrate that continuous patient monitoring with Portrait Mobile resulted in alarm data suitable…
Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today presented new pharmacodynamic data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of AU-007, the…
MUST Connect 2023 Singapore, a roadshow that helps Korean life science startups expand overseas by connecting them with global pharmaceutical companies and investors, was held on Oct. 11 (Wed.) and 12 (Thu.) at Singapore Science Park. Twelve Korean startups showcased…
Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results from its China and US IND enabling nonclinical studies for ANS014004 (“ANS01”), a novel small-molecule type II c-Met tyrosine kinase…
AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson’s Disease (PD). Mitokinin’s lead compound, a selective PINK1 activator, is…
Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology portfolio and addressing unmet needs of patients diagnosed with some of the…
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition…
Henry Schein, Inc. (Nasdaq: HSIC) announced today that Chairman and CEO Stanley M. Bergman was honored as Ragan’s 2023 Executive of the Year for Diversity and Inclusion. The Company also was honored by Ragan Communications, an industry leader in providing professional development, training and…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and three pipeline candidates in more than 15 types of cancer will be presented at the European Society…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (T3-4N2)…